GH Research price target lowered to $35 from $41 at Canaccord

Canaccord lowered the firm’s price target on GH Research to $35 from $41 and keeps a Buy rating on the shares. The analyst said based on our assumed clinical trial timelines, we are pushing our estimated launch timeline for GH001 for TRD out by a year to 2028E which causes us to lower out target.